Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach.

Literature DB >> 14638652

Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach.

Andreas Laupacis¹, J Michael Paterson, Muhammad Mamdani, Alaa Rostom, Geoffrey M Anderson.

Abstract

Mesh：

Year: 2003 PMID： 14638652 PMCID： PMC264957

Source DB: PubMed Journal: CMAJ ISSN： 0820-3946 Impact factor: 8.262

× No keyword cloud information.

12 in total

1. The impact of combined inhaled bronchodilator therapy in the treatment of COPD.

Authors: S Benayoun; P Ernst; S Suissa
Journal: Chest Date: 2001-01 Impact factor: 9.410

2. The role of databases in drug postmarketing surveillance.

Authors: E M Rodriguez; J A Staffa; D J Graham
Journal: Pharmacoepidemiol Drug Saf Date: 2001 Aug-Sep Impact factor: 2.890

3. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

Authors: Andreas Laupacis
Journal: CMAJ Date: 2002-01-08 Impact factor: 8.262

4. Look beyond budgets to the broader benefits.

Authors: Robert Dugal; Arvind Mani; Ken Potvin
Journal: Healthc Pap Date: 2002

5. Physician characteristics in relation to cardiovascular drugs commonly prescribed for hypertension in Nova Scotia.

Authors: F Burge; G Kephart; G Flowerdew; W Putnam; D G Comeau; A M Whelan; I Sketris; D Sclar
Journal: Can J Clin Pharmacol Date: 2001

6. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study.

Authors: C J Metge; J F Blanchard; S Peterson; C N Bernstein
Journal: Am J Gastroenterol Date: 2001-12 Impact factor: 10.864

7. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.

Authors: E Rahme; L Joseph; S X Kong; D J Watson; J LeLorier
Journal: Arthritis Rheum Date: 2000-04

8. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

Authors: Sebastian Schneeweiss; Alexander M Walker; Robert J Glynn; Malcolm Maclure; Colin Dormuth; Stephen B Soumerai
Journal: N Engl J Med Date: 2002-03-14 Impact factor: 91.245

9. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

Authors: Muhammad Mamdani; Paula A Rochon; David N Juurlink; Alex Kopp; Geoffrey M Anderson; Gary Naglie; Peter C Austin; Andreas Laupacis
Journal: BMJ Date: 2002-09-21

8. Development of a registry for monitoring psychotropic drug prescriptions: aims, methods and implications for ordinary practice and research.

Authors: Corrado Barbui; Michela Nosè; Gianluca Rambaldelli; Chiara Bonetto; Deborah Levi; Scott B Patten; Michele Tansella
Journal: Int J Methods Psychiatr Res Date: 2005 Impact factor: 4.035

8 in total

Gaps in the evaluation and monitoring of new pharmaceuticals: proposal for a different approach.

1. The impact of combined inhaled bronchodilator therapy in the treatment of COPD.

2. The role of databases in drug postmarketing surveillance.

3. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones?

4. Look beyond budgets to the broader benefits.

5. Physician characteristics in relation to cardiovascular drugs commonly prescribed for hypertension in Nova Scotia.

6. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study.

7. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.

8. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors.

9. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs.

Review 10. Drug policy: making effective drugs available without bankrupting the healthcare system.

1. Why don't we initiate more large simple randomized controlled trials?

2. Reporting process of randomized controlled trials.

3. Antidepressants and adverse effects in young patients: uncovering the evidence.

4. Vioxx: lessons for Health Canada and the FDA.

5. Patients beware.

6. Discussion point: should governments buy drug patents?

7. Pharmaceutical use and outcomes: always a need for a sober second look.

8. Development of a registry for monitoring psychotropic drug prescriptions: aims, methods and implications for ordinary practice and research.